Migraine trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Migraine. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 3 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy AdultsNCT07594769Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulations | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2026-06-10 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| HNGE | Hinge Health, Inc | A Comprehensive Digital Care Program for Migraine ManagementNCT07642414Mean Change in Monthly Migraine Days (MMDs) | Not applicable | Recruiting | Oct 2026 | ≤ 72 d | 2026-06-16 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigraineNCT06602479Efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine | Phase 2 | Recruiting | 2026-12-18 | in 120 d | 2026-05-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Migraine
most recently updated first192 studies match. Showing the first 100 of 192 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer | $155.3B | Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of MigraineNCT04743141The frequency and severity of on-treatment and treatment-emergent adverse events, serious adverse events, adverse events leading to discontinuation, clinically significant lab abnormalities | Phase 3 | Recruiting | Drug: Rimegepant (PF-07899801) | Acute Treatment of Migraine | 600 | 2021-04-28 | 2030-07-31 | in 1,441 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineNCT05711394Change from Baseline in Mean Monthly Migraine Days | Phase 3 | Recruiting | Drug: Atogepant, Placebo-Matching Atogepant | Episodic Migraine | 450 | 2023-05-01 | Mar 2028 | ≤ 589 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06417775Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period | Phase 3 | Active, not recruiting | Drug: Ubrogepant, Placebo for Ubrogepant | Migraine | 496 | 2024-09-10 | Nov 2027 | ≤ 467 d | 2026-08-14 |
| EVMN | Evommune, Inc. | $517M | Study of EVO756 in Adults With MigraineNCT07616128Mean change from baseline in the number of monthly migraine days (MMD) | Phase 2 | Recruiting | Drug: EVO756, Dose 1, EVO756, Dose 2, Placebo | Migraine | 330 | 2026-07-29 | Oct 2027 | ≤ 437 d | 2026-08-10 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)NCT05125302Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years | Phase 3 | Recruiting | Drug: Ubrogepant, Placebo-Matching Ubrogepant | Migraine | 1,059 | 2022-01-13 | May 2027 | ≤ 284 d | 2026-07-30 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigraineNCT06616194Number of migraine days per month | Phase 3 | Active, not recruiting | Drug: Rimegepant, Placebo | Migraine | 200 | 2024-11-15 | 2028-08-19 | in 730 d | 2026-07-30 |
| PFE | Pfizer | $155.3B | Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsNCT05156398Change from baseline in the mean number of migraine days per month as measured over the 12-week double-blind phase of the study in adolescents with episodic migraine | Phase 3 | Recruiting | Drug: Rimegepant, Placebo | Migraine | 640 | 2022-02-28 | 2031-11-29 | in 1,927 d | 2026-07-29 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineNCT07609914Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overall | Phase 4 | Recruiting | Drug: Rimegepant | Acute Treatment of Migraine | 400 | 2026-05-28 | 2028-05-15 | in 634 d | 2026-07-29 |
| IPN.PA | Ipsen | $15.5B | A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsNCT06625060Percentage of participants experiencing any Adverse Event (AEs) including treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESI) and AE leading to treatment discontinuation | Phase 2 | Recruiting | Biological: Corabotase, Corabotase dose A, Corabotase dose B · Other: Placebo | Episodic Migraine, Chronic Migraine | 641 | 2024-10-10 | 2027-10-31 | in 437 d | 2026-07-28 |
| ABBV | AbbVie | $457.5B | Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic MigraineNCT06603558observationalPercentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR) | — | Recruiting | Drug: Atogepant | Chronic Migraine, Episodic Migraine, Migraine | 3,000 | 2024-09-24 | May 2029 | ≤ 1,015 d | 2026-07-22 |
| AMGN | Amgen | $229.9B | Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineNCT03836040Change from baseline in MMDs | Phase 3 | Active, not recruiting | Drug: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3 · Other: Placebo | Migraine | 457 | 2019-07-19 | 2025-11-19actual | — | 2026-07-16 |
| IPN.PA | Ipsen | $15.5B | A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsNCT06047444Change from baseline at week 24 in monthly migraine days (MMD) | Phase 3 | Active, not recruiting | Biological: Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A · Other: Placebo | Chronic Migraine | 759 | 2023-10-12 | 2026-05-28actual | — | 2026-07-16 |
| IPN.PA | Ipsen | $15.5B | A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsNCT06047457Change from baseline in monthly migraine days (MMD) | Phase 3 | Active, not recruiting | Biological: Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A, Botulinum toxin type A · Other: Placebo | Episodic Migraine | 751 | 2023-09-29 | 2026-06-01actual | — | 2026-07-16 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Study of Eptinezumab in Pediatric Participants With Episodic MigraineNCT05897320Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12 | Phase 3 | Recruiting | Drug: Eptinezumab, Placebo | Episodic Migraine | 315 | 2023-06-08 | 2027-07-06 | in 320 d | 2026-07-14 |
| ABBV | AbbVie | $457.5B | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsNCT06810505Number of Participants Experiencing Adverse Events (AEs) | Phase 3 | Recruiting | Drug: Atogepant, Placebo for Atogepant | Chronic Migraine | 420 | 2025-02-13 | Mar 2031 | ≤ 1,684 d | 2026-07-14 |
| ABBV | AbbVie | $457.5B | Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United KingdomNCT07690215observationalPercentage of Participants Achieving a Rating of "Much Better" or "Very Much Better" Following Atogepant Initiation As Assessed by Patient's Global Impression of Change (PGI-C) | — | Not yet recruiting | — | Migraine | 200 | 2026-09-01 | Mar 2028 | ≤ 589 d | 2026-07-08 |
| PFE | Pfizer | $155.3B | A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in IndiaNCT07685769Incidence of Treatment-emergent adverse events (TEAEs) | Phase 4 | Not yet recruiting | Drug: Rimegepant 75 mg ODT | Acute Treatment of Migraine | 60 | 2026-07-17 | 2028-01-11 | in 509 d | 2026-07-06 |
| ABBV | AbbVie | $457.5B | Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With MigraineNCT05748483results2026-07-02Percentage of Participants Who Discontinued Treatment Due to Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: Atogepant, Placebo for Atogepant, Topiramate, Placebo for Topiramate | Migraine | 545 | 2023-10-07 | 2025-04-28actual | — | 2026-07-02 |
| PFE | Pfizer | $155.3B | A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.NCT06467370observationalSatisfaction with prescribed medication | — | Completed | — | Migraine | 467 | 2024-07-02 | 2025-03-11actual | — | 2026-06-30 |
| ABBV | AbbVie | $457.5B | Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In CanadaNCT06692881observationalPercentage of Participants Achieving Functional Disability Scale (FDS) Score of =0, no disability, able to function normally 4 hours post-dose | — | Completed | — | Migraine | 178 | 2025-02-12 | 2026-06-01actual | — | 2026-06-29 |
| LLY | Eli Lilly and Company | $1.15T | A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineNCT04396574results2026-06-25Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Terminatedsponsor's stated reason: Study terminated due to strategic business decision | Drug: Lasmiditan | Migraine | 558 | 2020-06-30 | 2025-12-04actual | — | 2026-06-25 |
| ABBV | AbbVie | $457.5B | Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigraineNCT06241313Percentage of Participants Achieving Pain Freedom at 2 Hours After the Double-Blind (DB) Dose for the First Attack | Phase 3 | Active, not recruiting | Drug: Atogepant, Placebo for Atogepant | Migraine | 1,300 | 2024-03-25 | 2025-07-07actual | — | 2026-06-24 |
| ABBV | AbbVie | $457.5B | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic MigraineNCT05216263results2026-06-16Number of Participants With Adverse Events (AEs) | Phase 3 | Completed | Drug: Atogepant | Chronic Migraine | 75 | 2022-03-22 | 2025-05-02actual | — | 2026-06-16 |
| HNGE | Hinge Health, Inc | $4.8B | A Comprehensive Digital Care Program for Migraine ManagementNCT07642414Mean Change in Monthly Migraine Days (MMDs) | Not applicable | Recruiting | Device: Neuromodulation Wearable Device · Other: Migraine Digital Care Program | Migraine, Migraine With Aura, Migraine Without Aura | 140 | Jun 2026 | Oct 2026 | ≤ 72 d | 2026-06-16 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigraineNCT05164172Number of Participants With Treatment Emergent Adverse Events | Phase 3 | Recruiting | Drug: Eptinezumab | Migraine | 600 | 2021-12-01 | 2028-04-30 | in 619 d | 2026-06-12 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive TreatmentsNCT06323928Change From Baseline in the Number of Monthly Migraine Days (MMDs) | Phase 2 | Completed | Drug: Lu AG09222, Placebo | Migraine | 874 | 2024-04-01 | 2026-01-16actual | — | 2026-06-12 |
| ABBV | AbbVie | $457.5B | Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineNCT05861427results2026-06-11Change From Baseline in Mean Monthly Migraine Days | Phase 3 | Completed | Drug: Atogepant, Placebo for Atogepant | Migraine | 524 | 2023-07-12 | 2025-03-01actual | — | 2026-06-11 |
| PFE | Pfizer | $155.3B | A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy AdultsNCT07594769Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulations | Phase 1 | Recruiting | Drug: ODT2 Test formulation, ODT Reference formulation | Migraine | 36 | 2026-05-08 | 2026-08-31 | in 11 d | 2026-06-10 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult ParticipantsNCT05653986observationalPercentage of Participants Achieving Meaningful Pain Relief | — | Completed | — | Migraine | 391 | 2022-12-18 | 2024-08-05actual | — | 2026-06-03 |
| ABBV | AbbVie | $457.5B | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineNCT06543914observationalPercentage of Participants Achieving a rating of "much better" or "very much better" as assessed by the Patient Global Impression of Change (PGI-C) | — | Active, not recruiting | — | Migraine | 1,314 | 2024-11-26 | Feb 2029 | ≤ 923 d | 2026-06-01 |
| PFE | Pfizer | $155.3B | Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive MedicationsNCT05518123results2026-05-22Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | Phase 4 | Completed | Drug: Rimegepant, Placebo | Migraine | 962 | 2022-11-07 | 2025-03-31actual | — | 2026-05-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian AdultsNCT05989048results2026-05-22Percentage of Participants With Pain Freedom at 2 Hours Post-dose | Phase 3 | Completed | Drug: Zavegepant, Placebo | Migraine | 1,414 | 2023-11-29 | 2025-05-30actual | — | 2026-05-22 |
| ABBV | AbbVie | $457.5B | A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigraineNCT06602479Efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine | Phase 2 | Recruiting | Drug: MEDI0618, Placebo | Migraine | 488 | 2024-10-07 | 2026-12-18 | in 120 d | 2026-05-19 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in KoreaNCT07497854observationalTo evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | — | Not yet recruiting | Drug: Rimegepant sulfate | Migraine With or Without Aura | 3,000 | 2026-10-01 | 2030-07-31 | in 1,441 d | 2026-05-15 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP MedicationsNCT06701526Number of Participants with Response of "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Scale | Phase 4 | Active, not recruiting | Drug: Eptinezumab | Migraine | 164 | 2024-12-18 | 2026-06-05 | — | 2026-05-13 |
| PFE | Pfizer | $155.3B | Consistency of Response With Rimegepant in Acute Treatment of MigraineNCT06898047observationalTime to Meaninful Pain Relief (MPR) post-dosing | — | Active, not recruiting | Drug: Rimegepant for acute migraine treatment | Migraine | 250 | 2025-11-15 | 2026-07-31 | — | 2026-05-07 |
| PFE | Pfizer | $155.3B | Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to RimegepantNCT05046613observationalMajor congenital malformation (birth defect) | — | Recruiting | Other: Rimegepant, Not taking Rimegepant | Migraine | 780 | 2021-09-23 | 2029-11-04 | in 1,172 d | 2026-05-05 |
| PFE | Pfizer | $155.3B | Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan UseNCT05509400results2026-04-21Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase | Phase 4 | Completed | Drug: Rimegepant, Placebo, Rimegepant | Migraine | 813 | 2022-10-18 | 2025-03-10actual | — | 2026-04-21 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult ParticipantsNCT05827887observationalUbrogepant (UBRO) Only: Percentage of Participants with Responder Status of "Extremely Satisfied" or "Satisfied" on a Single Item 7-Point Scale | — | Completed | — | Migraine | 226 | 2023-06-25 | 2026-01-28actual | — | 2026-04-03 |
| AMGN | Amgen | $229.9B | Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineNCT04252742results2024-08-30Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 | Phase 4 | Completed | Drug: Erenumab, Placebo | Migraine | 512 | 2020-09-15 | 2023-10-26actual | — | 2026-03-31 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigraineNCT06995729Maximum Observed Plasma Concentration (Cmax) | Phase 1 | Recruiting | Drug: Zavegepant | Acute Treatment of Migraine | 16 | 2025-05-16 | 2027-08-12 | in 357 d | 2026-03-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineNCT04396236Percentage of Participants with Pain Freedom (High Dose) | Phase 3 | Terminatedsponsor's stated reason: Study terminated due to strategic business decision | Drug: Lasmiditan, Placebo | Migraine | 851 | 2020-06-15 | 2025-11-12actual | — | 2026-03-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineNCT04616326Change from Baseline in the Number of Monthly Migraine Headache Days | Phase 3 | Active, not recruiting | Drug: Galcanezumab, Placebo | Chronic Migraine | 312 | 2020-11-25 | 2025-12-10actual | — | 2026-02-27 |
| ABBV | AbbVie | $457.5B | Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine AttacksNCT07310290observationalPercentage of Participants with Absence of moderate to severe headache over 24 hours post-dose during prodrome. | — | Recruiting | — | Migraine | 189 | 2026-01-27 | Mar 2027 | ≤ 223 d | 2026-02-10 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheNCT05452239results2025-12-04Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4 | Phase 4 | Completed | Drug: Eptinezumab, Placebo | Migraine, Medication Overuse Headache | 608 | 2022-07-01 | 2024-10-22actual | — | 2026-01-29 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Initiating Early Control of Migraine Pain and Associated SymptomsNCT04163185results2026-01-28Percentage of Subjects Achieving Headache Pain Freedom at Hour 2 | Phase 3 | Completed | Drug: AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo | Migraine | 302 | 2019-10-08 | 2020-03-16actual | — | 2026-01-28 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineNCT03432286Change from Baseline in the Number of Monthly Migraine Headache Days | Phase 3 | Active, not recruiting | Drug: Galcanezumab, Placebo | Episodic Migraine | 533 | 2018-03-14 | 2025-11-14actual | — | 2026-01-26 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | Therapy for Migraine Prevention in Children 6-11 Years of AgeNCT04050293results2025-11-21Change From Baseline in Monthly Migraine Days (MMDs) in Children 6 to 11 Years Old With Migraine. | Phase 4 | Terminatedsponsor's stated reason: Difficulty in recruitment | Drug: SPN-538, Placebo | Migraine Disorders, Headache Disorders | 26 | 2020-07-14 | 2023-03-01actual | — | 2026-01-22 |
| PFE | Pfizer | $155.3B | Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness SurveyNCT06680206results2026-01-22observationalNumber of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) | — | Completed | Drug: Rimegepant, Triptans | Migraine | 1,395 | 2024-10-10 | 2024-11-20actual | — | 2026-01-22 |
| AMGN | Amgen | $229.9B | Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineNCT03832998Change from baseline in MMDs | Phase 3 | Completed | Drug: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3 · Other: Placebo | Migraine | 284 | 2019-09-05 | 2025-01-08actual | — | 2026-01-20 |
| HLUN-B.CO | H. Lundbeck A/S | — | Eptinezumab as Preventive Treatment of Migraine in Adults With MigraineNCT04921384Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12) | Phase 3 | Completed | Drug: Placebo, Eptinezumab | Migraine | 981 | 2021-05-29 | 2024-10-01actual | — | 2026-01-14 |
| HLUN-B.CO | H. Lundbeck A/S | — | Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in JapanNCT05064371Number of Participants With Adverse Events (AEs) | Phase 3 | Completed | Drug: Eptinezumab | Migraine | 160 | 2021-09-21 | 2024-06-08actual | — | 2026-01-14 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.NCT05810038Mean change from the Observation Phase (OP) in the number of migraine days per month over the entire Double Blind Treatment (DBT) Phase | Phase 3 | Completed | Drug: Rimegepant, Placebo | Migraine | 787 | 2023-05-15 | 2025-08-25actual | — | 2026-01-14 |
| PFE | Pfizer | $155.3B | A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult ParticipantsNCT06103734Comparing efficacy of zavegepant with placebo in the acute treatment of migraine as measured by pain freedom at 2-hours post dose during the Double-Blind Treatment (DBT) Phase. | Phase 3 | Withdrawnsponsor's stated reason: Strategic decision to cancel the study based on adjusted clinical development plan. | Combination product: Zavegepant 10 mg, Placebo - Control 1, Placebo - Control 2 | Migraine | 0 | 2025-09-15 | 2027-08-02 | in 347 d | 2026-01-13 |
| PFE | Pfizer | $155.3B | Study of Pregnancy Outcomes in Women Exposed to Rimegepant During PregnancyNCT05198245observationalMajor congenital malformations, spontaneous abortions, fetal deaths/stillbirths, small for gestational age births | — | Active, not recruiting | Drug: Rimegepant, Various · Other: No intervention | Migraine | 1 | 2021-12-15 | 2028-04-17 | in 606 d | 2026-01-08 |
| ABBV | AbbVie | $457.5B | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineNCT04686136Percentage of Participants with at Least 1 Treatment Emergent Adverse Event | Phase 3 | Completed | Drug: Atogepant 60 mg | Episodic Migraine, Chronic Migraine | 596 | 2021-02-19 | 2025-10-20actual | — | 2025-12-18 |
| PFE | Pfizer | $155.3B | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensNCT05217927results2025-12-16Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12) | Phase 4 | Completed | Drug: Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing | Migraine | 1,415 | 2022-03-04 | 2024-10-22actual | — | 2025-12-16 |
| ABBV | AbbVie | $457.5B | Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During PregnancyNCT05158894observationalMajor Congenital Malformations (MCMs) | — | Recruiting | — | Migraine | 1,884 | 2023-01-10 | Jan 2036 | ≤ 3,451 d | 2025-12-15 |
| ABBV | AbbVie | $457.5B | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic MigraineNCT05028569results2025-12-09Change From Baseline in the Frequency of Monthly Migraine Days Across Months 5 and 6 | Phase 3 | Terminatedsponsor's stated reason: The study was terminated early due to lack of efficacy from the primary analysis results. | Drug: BOTOX, Placebo | Episodic Migraine | 775 | 2021-11-05 | 2024-11-06actual | — | 2025-12-09 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)NCT05550207Percentage of subjects with headache pain relief | Phase 3 | Completed | Drug: AXS-07 (meloxicam-rizatriptan) | Migraine | 100 | 2022-08-31 | 2024-11-27actual | — | 2025-12-02 |
| PFE | Pfizer | $155.3B | Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)NCT05399485results2025-07-14Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase | Phase 3 | Completed | Drug: Rimegepant, Placebo | Migraine | 496 | 2022-08-09 | 2024-01-18actual | — | 2025-11-18 |
| AMGN | Amgen | $229.9B | Aimovig Pregnancy Exposure RegistryNCT06150781observationalNumber of Infants Experiencing Major Congenital Malformations | — | Recruiting | Drug: erenumab-aooe | Migraine | 2,842 | 2021-01-27 | 2027-10-28 | in 434 d | 2025-11-04 |
| HNGE | Hinge Health, Inc | $4.8B | Evaluation of a Wearable Device for Acute Treatment of MigrainesNCT07015125Safety/Adverse Events | Not applicable | Completed | Device: Transcutaneous Electrical Nerve Stimulation (TENS) | Migraine, Migraine With or Without Aura, Migraine, Acute, Migraine Headache | 160 | 2025-06-09 | 2025-09-24actual | — | 2025-10-30 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Trial Investigating Lu AG09222 With Ubrogepant in Participants With MigraineNCT06578585Number of participants with treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Drug: Ubrogepant, Lu AG09222, Placebo | Migraine | 43 | 2024-09-13 | 2025-07-11actual | — | 2025-10-14 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheNCT03971071results2023-10-13Number of Participants With Absence of Medication Overuse Headaches (MOH) at Month 6 | Phase 4 | Completed | Drug: Erenumab 70 mg, Erenumab 140 mg, Placebo | Migraine Headache | 620 | 2019-10-07 | 2022-12-01actual | — | 2025-09-19 |
| PFE | Pfizer | $155.3B | Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine PreventionNCT05207865results2025-09-03Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to Intensity | Phase 4 | Completed | Drug: Rimegepant | Migraine, Episodic Migraine, Phonophobia, Photophobia | 441 | 2022-03-15 | 2024-07-02actual | — | 2025-09-03 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.NCT06532357results2025-08-11observationalNumber of Participants Classified as Per Responses for Satisfaction of Pain Intensity | — | Completed | — | Migraine | 1,536 | 2024-06-09 | 2024-06-10actual | — | 2025-08-22 |
| ABBV | AbbVie | $457.5B | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigraineNCT05707949Percentage of Participants with Adverse Events (AEs) | Phase 3 | Enrolling by invitation | Drug: Atogepant | Migraine Prophylaxis | 650 | 2023-06-05 | Apr 2032 | ≤ 2,080 d | 2025-08-11 |
| ABBV | AbbVie | $457.5B | A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic MigraineNCT04437433results2025-07-22Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs) | Phase 3 | Completed | Drug: Atogepant 60 mg | Chronic Migraine, Episodic Migraine | 186 | 2020-06-18 | 2024-06-11actual | — | 2025-07-22 |
| ABBV | AbbVie | $457.5B | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)NCT05127954Percentage of Participants with Adverse Events (AEs) | Phase 3 | Enrolling by invitation | Drug: Ubrogepant | Migraine | 1,200 | 2022-01-14 | Jan 2028 | ≤ 529 d | 2025-07-20 |
| PFE | Pfizer | $155.3B | A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine PreventionNCT04804033results2025-03-27Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12) | Phase 2/3 | Terminatedsponsor's stated reason: Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns. | Drug: BHV-3500 (zavegepant), Placebo | Migraine | 1,753 | 2021-03-26 | 2024-03-21actual | — | 2025-03-27 |
| PFE | Pfizer | $155.3B | Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)NCT05399459results2025-02-10Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose | Phase 3 | Completed | Drug: Rimegepant 25 MG, Rimegepant 75 MG, Placebo | Migraine | 897 | 2022-08-09 | 2024-01-19actual | — | 2025-03-07 |
| TNXP | Tonix Pharmaceuticals, Inc. | $217M | A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineNCT05679908results2025-02-25Mean Change in the Number of Monthly Migraine Headache Days | Phase 2 | Completed | Drug: TNX-1900, Placebo Nasal Spray | Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine | 88 | 2022-12-06 | 2023-10-08actual | — | 2025-02-25 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese ParticipantsNCT05371652results2025-02-20Treatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: Rimegepant 75mg Orally Disintegrating Tablets (ODT) | Acute Migraine | 241 | 2022-05-19 | 2024-02-06actual | — | 2025-02-20 |
| PFE | Pfizer | $155.3B | Reliability of Rimegepant or Triptans for the Acute Treatment of MigraineNCT06412965results2025-01-13observationalNumber of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) | — | Completed | — | Migraine Disorders | 528 | 2024-01-02 | 2024-01-03actual | — | 2025-01-13 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineNCT05264129results2024-10-08Number of Participants With Adverse Events (AEs) | Phase 4 | Completed | Drug: Atogepant, Ubrogepant | Episodic Migraine | 263 | 2022-03-07 | 2023-04-04actual | — | 2024-10-08 |
| AEON | AEON Biopharma, Inc. | $12M | Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine PreventionNCT05016661Incidence of Treatment Emergent Adverse Events | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to the analysis of the data not meeting the intended primary endpoint and key secondary endpoints. | Drug: ABP-450 | Migraine | 466 | 2021-10-19 | 2024-07-31actual | — | 2024-09-20 |
| AMGN | Amgen | $229.9B | A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With MigraineNCT04825678results2024-09-19Mean Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) Overall Satisfaction Scale Score at Week 24 by SoC | Phase 4 | Completed | Drug: Erenumab | Migraine | 240 | 2021-06-11 | 2023-09-28actual | — | 2024-09-19 |
| GAIA | Gaia AG | $36M | Effectiveness of a Dialogue-based Online Intervention Against MigraineNCT04276142Number of days with migraine headache | Not applicable | Completed | Behavioral: ceprica (additional to treatment as usual), active control intervention (additional to treatment as usual) | Migraine | 321 | 2023-06-05 | 2024-08-20actual | — | 2024-09-05 |
| AEON | AEON Biopharma, Inc. | $12M | Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsNCT04845178Change in Monthly Migraine Days | Phase 2 | Completed | Drug: ABP-450, Placebo | Migraine | 797 | 2021-03-01 | 2024-06-19actual | — | 2024-09-04 |
| OGN | Organon and Co | $3.6B | Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)NCT00092963Percentage of patients who are pain free at 2 hours postdose. | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day, Comparator: placebo / Duration of Treatment: 1 day | Migraine | 529 | 2004-08-17 | 2005-01-14actual | — | 2024-08-14 |
| OGN | Organon and Co | $3.6B | Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)NCT00095004Percentage of patients who are pain free at 2 hours postdose | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day, Comparator: placebo / Duration of Treatment: 1 day | Migraine | 167 | 2004-10-21 | 2005-04-01actual | — | 2024-08-14 |
| OGN | Organon and Co | $3.6B | Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)NCT00111709Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diary | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1 day, Comparator: placebo / Duration of Treatment - 1 day | Migraine | 393 | 2005-05-27 | 2006-02-24actual | — | 2024-08-14 |
| OGN | Organon and Co | $3.6B | Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)NCT00111722Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diary | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1day, Comparator: placebo / Duration of Treatment - 1 day | Migraine | 393 | 2005-05-27 | 2006-02-15actual | — | 2024-08-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic MigraineNCT05127486results2024-06-18Percentage of Participants With 50% Response Rate Across the 3-month Treatment Period. | Phase 4 | Completed | Drug: Galcanezumab, Rimegepant, Placebo, Placebo | Migraine, Episodic Migraine | 580 | 2021-12-06 | 2023-05-23actual | — | 2024-06-28 |
| PFE | Pfizer | $155.3B | Efficacy and Safety Trial of Rimegepant for Migraine Prevention in AdultsNCT03732638results2021-08-09Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase | Phase 2/3 | Completed | Drug: Rimegepant, Placebo | Migraine | 1,590 | 2018-11-14 | 2019-12-10actual | — | 2024-06-07 |
| AMGN | Amgen | $229.9B | Biomarker and Genetic Predictors of Erenumab Treatment ResponseNCT04265755results2024-06-07Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRS | Phase 4 | Completed | Drug: Erenumab | Migraine | 1,406 | 2020-10-26 | 2023-01-18actual | — | 2024-06-07 |
| HLUN-B.CO | H. Lundbeck A/S | — | Real World Effectiveness of Eptinezumab in Participants With MigraineNCT05284019results2024-05-29Change From Baseline in Patient-informed Most Bothersome Symptom (PI-MBS) Score at Week 24 | Phase 4 | Terminatedsponsor's stated reason: The study was terminated due to enrolment challenges. | Drug: Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab | Migraine | 32 | 2022-03-04 | 2023-02-17actual | — | 2024-05-29 |
| AMGN | Amgen | $229.9B | AMG 334 20160172 Pediatric Migraine PK Study.NCT03499119results2024-03-28Time to Maximum Concentration (Tmax) of Erenumab | Phase 1 | Completed | Drug: AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3 | Migraine | 53 | 2018-05-04 | 2021-11-23actual | — | 2024-05-28 |
| OGN | Organon and Co | $3.6B | A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine ProphylaxisNCT00812006results2011-01-27Pain Relief (PR) | Phase 3 | Completed | Drug: rizatriptan benzoate, Comparator: placebo | Migraine | 108 | 2009-03-24 | 2009-10-22actual | — | 2024-05-23 |
| OGN | Organon and Co | $3.6B | A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)NCT00894556results2011-01-20Pain Relief (PR) | Phase 3 | Completed | Drug: rizatriptan, Comparator: Placebo, Comparator: Sumatriptan | Acute Migraine | 109 | 2009-06-10 | 2010-01-12actual | — | 2024-05-10 |
| OGN | Organon and Co | $3.6B | A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)NCT01001234results2012-05-08Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age | Phase 3 | Completed | Drug: rizatriptan, placebo, rizatriptan, placebo | Migraine, Acute | 1,382 | 2009-11-30 | 2011-04-21actual | — | 2024-05-07 |
| OGN | Organon and Co | $3.6B | Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)NCT00516737results2009-04-14Number of Participants Who Are Pain Free at 2 Hours Post-Dose | Phase 3 | Completed | Drug: Comparator: rizatriptan benzoate, Comparator: Placebo | Migraine | 207 | 2007-10-03 | 2008-04-08actual | — | 2024-04-22 |
| OGN | Organon and Co | $3.6B | Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)NCT00604812results2009-09-02Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs | Phase 1 | Completed | Drug: rizatriptan benzoate (5 mg), rizatriptan benzoate (10 mg), Rizatriptan 5 mg Placebo, Rizatriptan 10 mg Placebo | Migraine Disorders | 31 | 2007-12-17 | 2010-09-17actual | — | 2024-04-19 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive TreatmentsNCT05133323results2024-02-08Change From Baseline in the Number of Monthly Migraine Days (MMDs) | Phase 2 | Completed | Drug: Lu AG09222, Placebo | Migraine | 237 | 2021-11-11 | 2023-01-19actual | — | 2024-03-13 |
| AMGN | Amgen | $229.9B | A Controlled Trial of Erenumab in Migraine PreventionNCT03812224results2021-03-04Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment Period | Phase 3 | Completed | Drug: Erenumab, Placebo | Migraine | 261 | 2019-04-12 | 2020-03-16actual | — | 2024-02-21 |
| PFE | Pfizer | $155.3B | Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of MigraineNCT04574362results2023-12-14Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose | Phase 3 | Completed | Drug: Rimegepant, Placebo | Acute Migraine | 1,648 | 2020-10-22 | 2021-11-24actual | — | 2023-12-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3451838 in Participants With MigraineNCT04498910results2023-11-28Change From Baseline in the Number of Monthly Migraine Headache Days During 1-Month | Phase 2 | Completed | Drug: LY3451838, Placebo | Migraine | 38 | 2020-11-16 | 2022-11-09actual | — | 2023-11-28 |
| AMGN | Amgen | $229.9B | Study of Sustained Benefit of AMG334 in Adult Episodic Migraine PatientsNCT03927144results2022-10-25Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12 | Phase 4 | Completed | Drug: AMG334, Oral Prophylactic | Episodic Migraine | 621 | 2019-05-15 | 2021-10-01actual | — | 2023-11-18 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)NCT04068051results2023-10-10Long-term Safety of Chronic Intermittent Use of AXS-07 | Phase 3 | Completed | Drug: AXS-07 | Migraine | 706 | 2019-07-06 | 2020-09-22actual | — | 2023-10-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Migraine is matched — 12 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Migraine
- Episodic Migraine
- Migraine Disorders
- Migraine Headache
- Chronic Migraine
- Acute Migraine
- Acute Treatment of Migraine
- Migraine, With or Without Aura
- Migraine With or Without Aura
- Migraine Prophylaxis
- Migraine, Acute
- Treatment for Prevention of Chronic Migraine
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Migraine” (a text search, wider than this page)